Literature DB >> 562994

Diagnostic and therapeutic reevaluation of patients with intractable epilepsy.

R J Porter, J K Penry, J R Lacy.   

Abstract

Intensive monitoring techniques were used to improve seizure diagnosis and control in 23 patients with intractable epilepsy: (1) Video recording of clinical seizures and the ictal EEG, (2) long-term telemetered EEG recordings, and (3) frequent determination of plasma antiepileptic drug concentrations. Patients were monitored in the hospital for an average of 8 weeks and after discharge were followed for an average of 8 months. At follow-up, 70 percent of the patients continued to have improved seizure control as compared with baseline studies, 83 percent had decreased toxicity, and about half had made gains in social adjustment. Use of the techniques described can make a significant contribution to patients previously considered intractable to therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 562994     DOI: 10.1212/wnl.27.11.1006

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

Review 1.  The Anticonvulsant Screening Program of the National Institute of Neurological Disorders and Stroke, NIH: History and Contributions to Clinical Care in the Twentieth Century and Beyond.

Authors:  Roger J Porter; Harvey J Kupferberg
Journal:  Neurochem Res       Date:  2017-03-09       Impact factor: 3.996

2.  Routine EEG vs. intensive monitoring in the evaluation of intractable epilepsy.

Authors:  T R Perry; R J Gumnit; J R Gates; I E Leppik
Journal:  Public Health Rep       Date:  1983 Jul-Aug       Impact factor: 2.792

3.  Epileptic seizure disorders. Developments in diagnosis and therapy.

Authors:  E Niedermeyer; W Froescher; R S Fisher
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

4.  Electroencephalography and phenytoin toxicity in mentally retarded epileptic patients.

Authors:  M Iivanainen; M Viukari; A M Seppäläinen; E P Helle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-03       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.